Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb Buys Eyeonics, Enters Premium IOL Market With Crystalens

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb will enter the fast-growing premium intraocular lens market for the first time through its acquisition of Crystalens maker Eyeonics under a pact announced Jan. 20

You may also be interested in...



NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase

Abbott will strengthen its premium intraocular lens offerings and enter the accommodating IOL market for the first time through its $400 million purchase of Visiogen, announced Sept. 2

Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase

Abbott will strengthen its premium intraocular lens offerings and enter the accommodating IOL market for the first time through its $400 million purchase of Visiogen, announced Sept. 2

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel